-
A number of neurotrophic factors have great promise for the treatment of neurologic diseases. Prior work showed that a number of neurotrophic factors appeared to have promise for treating ALS, as well as peripheral neuropathy.
-
This is the first reported clinical trial of the effects of creatine in sporadic ALS patients. The trial was carried out in The Netherlands.
-
In one of the more bizarre stories of the year, the FDA has uncovered files of counterfeit Procrit (epoetin alfaJohnson & Johnson) in routine surveillance. To make matters worse, the fake vials have been contaminated with bacteria and many contain no active ingredient.
-
Editors Note: The following reports from the annual scientific sessions of the American College of Cardiology held March 30 to April 2, 2003, were obtained by handwritten notes, press releases, and news reports.
-
In one of the more bizarre stories of the year, the FDA has uncovered files of counterfeit Procrit (epoetin alfaJohnson & Johnson) in routine surveillance. To make matters worse, the fake vials have been contaminated with bacteria and many contain no active ingredient.
-
-
Synopsis: When RALES and EPHESUS are considered together, one clearly can recommend the use of an aldosterone receptor blocker for all very ill patients with congestive heart failure and significant LV dysfunction, whether or not related to acute myocardial infarction.
-
Rheumatoid arthritis should be recognized as a marker of increased risk for myocardial infarction.
-
The FDA recently approved a new class of antiretroviral drug for treatment of patients with resistant HIV infections.
-
Keeping the INR in the range of 1.5 to 2.0 is safe and effective.
